-
Wall Street Focused On Tesla's Batteries, Valuation Heading Into Earnings
Monday, August 3, 2015 - 11:57am | 774Read More...Tesla Motors Inc (NASDAQ: TSLA) is scheduled to report its second-quarter results after Wednesday's market close. The Estimize community is projecting the company to lose $0.50 per share on revenue of $1.166 billion. This compares to the Wall Street consensus estimate calling for a loss of $0...
-
The Rationale To Sell LinkedIn Stock
Friday, July 31, 2015 - 8:37am | 379Read More...In a report published Friday, Brean Capital analyst Sarah Hindlian maintained a Sell rating and price target of $172 on LinkedIn Corp (NYSE: LNKD). Although the headline results for 2Q15 appear strong, the analyst believes that they were actually weak but masked by Lynda.com. Weak Q2...
-
Why Is The Medicines Company Stock Falling? This Analyst May Have An Answer
Wednesday, July 29, 2015 - 2:53pm | 337Read More...Shares of The Medicines Company (NASDAQ: MDCO) tumbled more than 5 percent Wednesday after the company reported its second-quarter results before the market opened. Shares opened the day for trading at $32.77 and quickly moved lower to $31.08 before slightly rebounding. Umer Raffat, Evercore ISI's...
-
With The Teva Money, Allergan Could Engage In 'Large M&A' Next: Evercore ISI
Monday, July 27, 2015 - 4:25pm | 340Read More...In a report published Monday, Evercore ISI analyst Umer Raffat said that with its capital structure being “reloaded” following the deal with Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA), global pharma giant Allergan PLC (NYSE: AGN) is now set to “further accelerate...
-
Biogen's Final Catalyst Of 2015 Is A 'Coin Flip,' Evercore ISI Analyst Says
Friday, July 24, 2015 - 9:12am | 257Read More...In a note to clients on Friday, Evercore ISI analyst Mark Schoenebaum commented that investors were expecting Biogen Inc (NASDAQ: BIIB) to report a "weak quarter" but its print actually came in "probably even worse" than expected. Biogen earned $4.22 per share in the second quarter, beating the $4....
-
Evercore ISI's Schoenebaum Breaks Down Celgene-Receptos Merger
Wednesday, July 22, 2015 - 2:19pm | 385Read More...In a new presentation, Evercore ISI analyst Mark Schoenebaum breaks down the recently announced Celgene Corporation (NASDAQ: CELG) buyout of Receptos Inc (NASDAQ: RCPT). The deal is valued at about $7.2 billion, and the $232/share price that Celgene is paying represents about a 12 percent premium...
-
Evercore ISI's Mark Schoenebaum: New Eli Lilly Data 'Incrementally Positive'
Wednesday, July 22, 2015 - 10:49am | 141Read More...In a report published Wednesday, Evercore ISI analyst Mark Schoenebaum said that Eli Lilly and Co (NYSE: LLY) had provided additional data in mild Alzheimer's disease (AD) patients from EXPEDITION-EXT, the extension study to the Phase 3 EXPEDITION 1 and 2 trials of solanezumab. Analyst Mark...
-
SunTrust Initiates PayPal At Buy; What Else Are Analysts Saying?
Monday, July 20, 2015 - 10:27am | 462Read More...In a report published Monday, SunTrust Robinson Humphrey analyst Bob Peck initiated coverage of Paypal Holdings Inc (NASDAQ: PYPL) with a Buy rating and $45 price target, noting that the "leading enabler" of online and in-app payments has "ample capacity" to fund its future...
-
Evercore Upgrades Guess On Improvements In Europe
Wednesday, July 15, 2015 - 9:27am | 357Read More...In a report published Wednesday, Evercore analyst Omar Saad upgraded the rating on Guess?, Inc. (NYSE: GES) from Sell to Hold, while raising the target price to $22, following the announcement that CEO Pail Marciano is to step down in August and will be succeeded by Victor Herrero, currently Head...
-
Workday Upgraded At Evercore ISI, Investors Need To Be Patient
Tuesday, July 14, 2015 - 10:32am | 215Read More...In a report published Tuesday, Evercore ISI analyst Kirk Materne upgraded the rating on Workday Inc (NYSE: WDAY) from Hold to Buy, saying that the recent pullback in the company's shares provided "an interesting opportunity" for investors with a long-term view. Workday's shares had risen by 22...
-
Evercore ISI Analyst Gives Highlights From Vertex's Orkambi Call
Sunday, July 5, 2015 - 2:26pm | 189Read More...In a report published Friday, Evercore ISI analyst Mark Schoenebaum mentioned that the Orkambi approval ROW of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is on track with the EMA approval expected later in 2015. According to the Evercore ISI report, "Royalties… Will move into low double...
-
AAIC Is Coming: Here's What To Expect, Biogen And Eli Lilly Investors
Friday, July 3, 2015 - 10:21am | 395Read More...In a report published Friday, Evercore ISI analyst Mark Schoenebaum mentioned the abstracts and companies he would be tracking during the upcoming AAIC. This could include aducanumab by Biogen Inc (NASDAQ: BIIB) and solanezumab by Eli Lilly and Co (NYSE: LLY). AAIC is scheduled between July...
-
Evercore Technician: Tesla To Touch $300 Soon
Wednesday, July 1, 2015 - 1:54pm | 323Read More...Shares of Tesla Motors Inc (NASDAQ: TSLA) have been on a massive run, up more than 40 percent ($81) in last three months. According to Rich Ross, Managing Director and Head of Technical Analysis at Evercore ISI, this momentum will continue in the future. He was on CNBC recently to share his...
-
Evercore ISI Initiates Community Healthcare At Buy
Friday, June 26, 2015 - 9:25am | 45Read More...Analysts at Evercore ISI initiated coverage on Community Healthcare Trust Inc (NYSE: CHCT) with a Buy rating. The target price for Community Healthcare is set to $22. Community Healthcare shares fell 0.31 percent to close at $19.05 yesterday.
-
IPO Outlook: Is The Market Hungry For Chicken Processor Wayne Farms?
Monday, June 22, 2015 - 2:02pm | 1371Read More...Wayne Farms Inc (NASDAQ: WNFM), the sixth largest producer and processor of broiler chickens, plans to raise over $300 million in its IPO this Thursday. The company is being spun off from parent Continental Grain. Wayne Farms expects to offer over 12.8 million shares between $18 and $21 per share...
